Cargando…
Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡
AIMS: To evaluate the safety profile and efficacy of bone marrow mononuclear cells (BMMNC) transplantation for ST-segment elevation myocardial infarction (STEMI) by assessing patients and their left ventricular function at up to 4 years follow-up. METHODS AND RESULTS: Eighty-six patients with STEMI...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726958/ https://www.ncbi.nlm.nih.gov/pubmed/19508995 http://dx.doi.org/10.1093/eurheartj/ehp220 |
_version_ | 1782170645629501440 |
---|---|
author | Cao, Feng Sun, Dongdong Li, Chengxiang Narsinh, Kazim Zhao, Li Li, Xue Feng, Xuyang Zhang, Jun Duan, Yunyan Wang, Jing Liu, Dingjing Wang, Haichang |
author_facet | Cao, Feng Sun, Dongdong Li, Chengxiang Narsinh, Kazim Zhao, Li Li, Xue Feng, Xuyang Zhang, Jun Duan, Yunyan Wang, Jing Liu, Dingjing Wang, Haichang |
author_sort | Cao, Feng |
collection | PubMed |
description | AIMS: To evaluate the safety profile and efficacy of bone marrow mononuclear cells (BMMNC) transplantation for ST-segment elevation myocardial infarction (STEMI) by assessing patients and their left ventricular function at up to 4 years follow-up. METHODS AND RESULTS: Eighty-six patients with STEMI who had successfully undergone percutaneous coronary intervention (PCI) were randomized to receive intracoronary injection of BMMNC (n = 41) or saline (n = 45). Left ventricular ejection fraction, as evaluated by UCG, was markedly improved at 6 months (0.484 ± 0.5 vs. 0.457 ± 0.6, P = 0.001), 1 year (0.482 ± 0.7 vs. 0.446 ± 0.6, P < 0.001), and 4 years (0.505 ± 0.8 vs. 0.464 ± 0.8, P < 0.001) after BMMNC transplant when compared with control group. However, the current cell therapy did not improve the myocardial viability of the infarcted area as assessed by single-photon emission computed tomography analysis at 4 years post-transplant (0.263 ± 0.007 in BMMNC group vs. 0.281 ± 0.008 in control group, P = 0.10). During the follow-up period, one control group case (2.2%) of in-stent restenosis was confirmed by coronary angiography and underwent repeat PCI. Also during follow-up, one death (2.2%) occurred in the control group, and one patient (2.4%) in the BMMNC group had transient acute heart failure. CONCLUSION: This study indicates that intracoronary delivery of autologous BMMNC is safe and feasible for STEMI patients who have undergone PCI, and can lead to long-term improvement in myocardial function. |
format | Text |
id | pubmed-2726958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-27269582009-08-20 Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡ Cao, Feng Sun, Dongdong Li, Chengxiang Narsinh, Kazim Zhao, Li Li, Xue Feng, Xuyang Zhang, Jun Duan, Yunyan Wang, Jing Liu, Dingjing Wang, Haichang Eur Heart J Clinical Research AIMS: To evaluate the safety profile and efficacy of bone marrow mononuclear cells (BMMNC) transplantation for ST-segment elevation myocardial infarction (STEMI) by assessing patients and their left ventricular function at up to 4 years follow-up. METHODS AND RESULTS: Eighty-six patients with STEMI who had successfully undergone percutaneous coronary intervention (PCI) were randomized to receive intracoronary injection of BMMNC (n = 41) or saline (n = 45). Left ventricular ejection fraction, as evaluated by UCG, was markedly improved at 6 months (0.484 ± 0.5 vs. 0.457 ± 0.6, P = 0.001), 1 year (0.482 ± 0.7 vs. 0.446 ± 0.6, P < 0.001), and 4 years (0.505 ± 0.8 vs. 0.464 ± 0.8, P < 0.001) after BMMNC transplant when compared with control group. However, the current cell therapy did not improve the myocardial viability of the infarcted area as assessed by single-photon emission computed tomography analysis at 4 years post-transplant (0.263 ± 0.007 in BMMNC group vs. 0.281 ± 0.008 in control group, P = 0.10). During the follow-up period, one control group case (2.2%) of in-stent restenosis was confirmed by coronary angiography and underwent repeat PCI. Also during follow-up, one death (2.2%) occurred in the control group, and one patient (2.4%) in the BMMNC group had transient acute heart failure. CONCLUSION: This study indicates that intracoronary delivery of autologous BMMNC is safe and feasible for STEMI patients who have undergone PCI, and can lead to long-term improvement in myocardial function. Oxford University Press 2009-08 2009-06-09 /pmc/articles/PMC2726958/ /pubmed/19508995 http://dx.doi.org/10.1093/eurheartj/ehp220 Text en Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org http://creativecommons.org/licenses/by-nc/2.0/uk/ The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org |
spellingShingle | Clinical Research Cao, Feng Sun, Dongdong Li, Chengxiang Narsinh, Kazim Zhao, Li Li, Xue Feng, Xuyang Zhang, Jun Duan, Yunyan Wang, Jing Liu, Dingjing Wang, Haichang Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡ |
title | Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡ |
title_full | Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡ |
title_fullStr | Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡ |
title_full_unstemmed | Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡ |
title_short | Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡ |
title_sort | long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with st-segment elevation myocardial infarction: 4 years follow-up‡ |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726958/ https://www.ncbi.nlm.nih.gov/pubmed/19508995 http://dx.doi.org/10.1093/eurheartj/ehp220 |
work_keys_str_mv | AT caofeng longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup AT sundongdong longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup AT lichengxiang longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup AT narsinhkazim longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup AT zhaoli longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup AT lixue longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup AT fengxuyang longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup AT zhangjun longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup AT duanyunyan longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup AT wangjing longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup AT liudingjing longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup AT wanghaichang longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup |